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Pituitary Alterations Involved in the Decline of Growth
Hormone Gene Expression in the Pituitary of Aging Rats
Miriam G. San Frutos,1 Lucinda Cacicedo,2 Carolina F. Me´ndez,1 David Vicent,1
Miguel Gonza´lez,3 and Franco Sa´nchez-Franco1
1Endocrine Service and 3Immunology Service, Hospital Carlos III, Madrid, Spain.
2Endocrine Service, Hospital Ramo´n y Cajal, Madrid, Spain.
Growth hormone (GH) declines during aging. This study investigates whether pituitary
constitutive alterations may be involved in the GH decline. Two groups of male Wistar rats were
studied (young: 3-month-old; old: 24-month-old). The old rats showed lower pituitary GH
messenger RNA (mRNA) levels, immunoreactive rat (IR)-GH content, and GH secretion with no
difference in pituitary Pit-1 and cAMP-response element-binding protein (CREB) expression.
Pituitary GH releasing hormone receptor (GHRH-R), GH secretagogue receptor (GHS-R), sstr2,
and sstr5 mRNA levels were significantly reduced in old rats. The percentage of GH
immunoreactive cells was similar in both groups. In vitro, pituitary IR-GH response to GHRH,
forskolin (FK), ghrelin, and insulin-like growth factor I (IGF-I) was similar when compared with
respective basal secretion and somatostatin-diminished GHRH- and ghrelin-induced IR-GH
release in both groups. These results indicate that, as somatotrope function is maintained in aging,
the changes observed in GH gene expression and secretion could be reversed by GHS.
IT is now evident that the joint decline in growth hormone(GH) secretion (1,2) rate and plasma insulin-like growth
factor I (IGF-I) concentrations (3,4) is one of the best char-
acterized events that occurs with aging (5). GH secretion in
male rats is pulsatile in nature (6), and in old male rats the
amplitude and duration of the pulses decrease, but the
periodicity appears to be similar to that present in younger
rats (7).
Previous studies from our laboratory indicated that
alterations in GH gene expression might account for the
decrease of GH secretion in aging (8). These studies also
demonstrated that the decrease of GH gene expression and
secretion are due to aging and not to the increase in body
weight that occurs with aging. We also confirmed that aging
is not a physiological situation of GH resistance, and that the
peripheral alterations of the GH–IGF-I system are reversible
by repetitive exogenous GH administration (9).
GH is physiologically regulated by the opposite actions of
at least two specific neuropeptides, growth hormone
releasing hormone (GHRH) and somatostatin (SS) (10).
GHRH stimulates GH secretion and GH gene expression,
whereas SS inhibits GH secretion through the activation of
their specific receptors: GHRH receptor (GHRH-R) and SS
receptors (11,12). It has recently been reported that ghrelin,
a potent acylated peptide synthesized in the stomach,
anterior pituitary gland, and hypothalamus, drives GH
secretion via a novel cascade of hypothalamo-hypophyseal
mechanisms with the participation of the GH secretagogue
receptor (GHS-R) (13–16). Five different SS receptor
subtypes (sstr1–sstr5) have recently been cloned and
characterized in various species, including the human, rat,
and mouse (17,18). Sstr2 and sstr5 are the most abundant
and functionally active SS receptor subtypes in the rat
pituitary, where they mediate the suppressive action of SS
on GH secretion (19,20). Binding of SS to its receptor
inhibits the signal transduction systems for both GHRH and
GHS, and produces a reduction of basal and stimulated GH
secretion (21,22). Pituitary expression of the GH gene is
dependent on a pituitary-specific transcription factor-1 (Pit-1)
(23). Pit-1 transcription is regulated by the cAMP-response
element-binding protein (CREB), a positive autoregulation
by its own gene product, and by other pituitary-specific
transcription factors (24–26). In addition, it has been
reported that CREB plays a role in pituitary GH production
and somatotrope expansion (27).
It is not known why GH secretion declines with
increasing age. Possible mechanisms, alone or in combina-
tion, include reduced GHRH secretion or action, increased
SS secretion or action, and reduced somatotrope number or
function. It has been suggested that changes in the specific
hypothalamic regulatory hormones might be the primary
etiological factor (28), but primary pituitary alterations
should also be considered because early studies suggested
that it is the pituitary itself that undergoes senescent damage
(29). It is known that somatotrope responsiveness to the
specific regulatory neuropeptides undergoes wide variations
during the rat life span. Somatotrope responsiveness to
GHRH gradually decreases with age, although there is no
general consensus on this point (30,31). Some studies have
shown a diminished capacity of the secretagogues to release
GH in vivo with age (32), and a higher sensitivity to SS with
aging has also been postulated (33).
Circulating IGF-I, a primary target gene of GH action,
also participates in the negative feedback regulation of GH
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by acting at the hypothalamus and the pituitary levels
through an endocrine long loop feedback (34). IGF-I
decreases GH secretion and messenger RNA (mRNA)
levels in primary rat pituitary cells and human pituitary
tumor cell cultures (35,36). It has been postulated that an
increase in the sensitivity of the somatotrope to the
inhibitory action of IGF-I may be involved in the GH
decline with aging (37).
The aim of this study was to elucidate whether the decline
in GH gene expression during aging is a constitutive
alteration of the pituitary gland due to changes in some of
the pituitary transcription factors involved in GH gene
expression, such as pituitary Pit-1 and/or CREB; an
alteration of pituitary GHRH-R, GHS-R, SS subtypes sstr2
and sstr5 receptors and/or IGF-I-R, or a reduction of
somatotrope number or function. The involvement of these
age-related pituitary alterations was determined by analyz-
ing the responsiveness of pituitary cells of aging rats to the
GH stimulatory factors GHRH and ghrelin and to the GH
inhibitory factors SS and IGF-I. The outcome of this study
might provide the experimental support for a potential
reversibility of these alterations using secretagogues in older
humans.
METHODS
Animals
Young adult (3-month-old) and old (24-month-old)
male Wistar rats were obtained from the Animal
Experimental Center (Universidad de Alcala´, Madrid,
Spain). Upon arrival at our institution, animals were
housed in a specific pathogen-free facility and maintained
on a 12-hour light/dark cycle. Water and food were
available ad libitum to all animals. The maintenance and
handling of the animals were performed as recommended
by the National Institutes of Health (NIH) guidelines on
the care and use of laboratory animals, according to the
principles expressed in the Declaration of Helsinki and
with the guidelines on protection of animals used in
scientific research set by the Spanish Real Decreto 223/
1988 March 14, 1989 and Orden October 13, 1989. For
pituitary tissue extract studies, four experiments using
three male Wistar rats in each group were performed. For
the pituitary cell culture studies, four experiments were
done with three to four dishes used per condition. The
animals were killed by decapitation, and their pituitary
glands were removed under sterile conditions; the neuro-
hypophyses were discarded, and the anterior pituitaries
rapidly frozen on dry ice and stored at 808C until ex-
traction and quantification of the different parameters, or
collected and mechanico-enzymatically dispersed for
preparation of primary pituitary cell cultures.
Reagents
Rat GHRH (1-43) was purchased from Neo System
(Strasbourg, France). Rat ghrelin and SS-14 were obtained
from Bachem (Torrance, CA). Recombinant human IGF-I
was obtained from PeproTech EC (London, U.K.). 125I,
[32P]deoxy-CTP and [32P]ribo-UTP were obtained from
Amersham Pharmacia Biotech (Amersham, Buckingham-
shire, U.K.). Poly-L-ornithine was obtained from Sigma (St.
Louis, MO).
Buffers and Media
Dulbecco’s modified Eagle’s medium (DMEM), fetal
calf serum (FCS), Hank’s balanced salt solution (HBSS),
phosphate-buffered saline (PBS), penicillin–streptomycin,
and L-glutamine were obtained from BioWhittaker (Walkers-
ville, MD). Defined medium consisted of DMEM (glucose
1 g/L) supplemented with: bovine serum albumin (BSA) 1%,
HEPES (15 mM), hydrocortisone (0.1 lM), T3 (0.5 nM),
transferrin (10 lM), glucagon (10 nM), and parathyroid
hormone (PTH) (0.2 nM) (obtained from Sigma) and
L-glutamine (4 mM) and penicillin–streptomycin (100 U/mL).
Cell Cultures and Experimental Design
Pituitary cells from the two groups of rats were cultured
as previously described (38). Anterior pituitaries of 3-
month-old and 24-month-old male Wistar rats were
collected and mechanico-enzymatically dispersed with
0.1% papain, 0.1% neutral protease, and 0.1% DNase for
1 hour at 378C. The dispersed pituitary cells were
resuspended in defined medium containing FCS (5%),
plated on poly-L-ornithine-coated culture plates (24-well)
and seeded at a density of 4 3 105 cells per dish. Cultures
were kept in a humidified atmosphere of 5% CO2/95% air
at 378C. After a stabilizing period of 72 hours in serum-
supplemented defined medium (5% FCS), cells were
preincubated in defined medium (serum free) for 4 hours
and treated with GHRH, forskolin (FK), ghrelin and/or
SS-14 for another 4 hours, and with recombinant human
IGF-I for another 72 hours. At the end of the experiments,
media were removed, and cells acidified with 0.1 M
hydrochloric acid ClH; both were boiled for 5 minutes
and centrifuged for 30 minutes at 20,000 g. The super-
natants were immediately frozen and stored at 208C until
being analyzed for GH concentration by radioimmunoassay
(RIA).
Cell Culture Validation
To determine the behavior of the somatotropes from young
and old rats in our in vitro system, anterior pituitaries of 3-
month-old and 24-month-old male Wistar rats were plated on
six-well culture plates and seeded at a density of 13106 cells
per dish as previously described. After the stabilizing period,
media were replaced and the cells were incubated for 72
hours. To test for IR-GH release, aliquots of media were taken
after 4, 8, 24, 48, and 72 hours. To test for GH mRNA levels,
cells were obtained after 4 or 72 hours, washed with PBS, and
removed in TRIzol reagent (Life Technologies, Inc., Grand
Island, NY) for total mRNA extraction and Northern blot
analysis as described below. Preliminary studies demonstrated
that GH release increased with increasing doses of GHRH,
GHS, and FK and decreased with increasing doses of SS or
IGF-I. Time-course studies showed that these effects were
more evident 4 hours after GHRH, GHS, FK, and SS and
72 hours after IGF-I addition.
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GH RIA
Immunoreactive rat GH (IR-GH) in pituitary extracts and
culture media was measured by RIA using the National
Pituitary Hormone Distribution Program rat hormone Kit
(National Institute of Diabetes and Digestive and Kidney
Diseases [NIDDKD], Bethesda, MD) with a sensitivity limit
of 0.8 lg/L. IR-GH was measured in individual rats or
wells. All samples from each experiment were measured in
the same RIA to exclude inter-assay variation, and GH
values were expressed as percentages of the 3-month-old
control group.
Western Analysis
Pituitaries were lysed in a buffer containing 50 mM NaCl,
0.01 M Tris-HCl (pH 7.6), 0.001 M EDTA, 0.1% Nonidet
P-40, aprotinin at 1 lg/mL, and phenylmethylsulfonyl fluo-
ride (PMSF) at 100 lg/mL. Total protein extracts (10 lg)
were resolved by sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS–PAGE) and transferred to a poly-
vinylidene fluoride (PVDF) membrane. After blocking the
membranes, immunodetection was performed using rabbit
anti-Pit-1 (1:5000 dilution; Santa Cruz Biotechnology,
Santa Cruz, CA), anti-CREB (1:1000; Cell Signaling Tech-
nologies, Beverly, MA), anti-P-CREB (Ser133) (1:1000;
Upstate Biotechnology, Lake Placid, NY), and anti-IGF-
I-Rb (1:1000; Santa Cruz Biotechnology) followed by
incubation with a goat peroxidise-conjugated antirabbit
secondary antibody (1:1000 dilution; DAKO, Glostrup,
Denmark). Immunoreactive bands were visualized using an
enhanced chemiluminescence-detecting system (Amersham).
Quantification of the intensities of the autoradiographic
bands was done by scanning densitometric analysis of
the x-ray films using National Institutes of Health (NIH)
Image 1.47 and Adobe-Photoshop 2.0 software (Macintosh).
As a loading control, the membranes were systemati-
cally stained with Coomassie brilliant blue R-250 solution
(0.125%), for 1 hour at room temperature, to validate the
Western blot.
Northern Analysis
Total RNA was extracted using TRIzol reagent, according
to the protocol supplied by the manufacturer. A fraction of
2–15 lg was subjected to electrophoresis in a 1% agarose/
0.66 mol/L formaldehyde gel, followed by electrotransfer to
a nylon membrane (Nytran; Schleicher & Schuell, Keene,
NH) and ultraviolet cross-linking (Hoefer Scientific Instru-
ments, San Francisco, CA). The complementary DNA
(cDNA) probes for GH, GHRH-R, and Pit-1 were labeled
with [32P]deoxy-CTP (3000 Ci/mmol), and CREB riboprobe
was labeled with [32P]ribo-UTP (3000 Ci/mmol). Prehybrid-
ization was carried out for 16 hours at 428C, and membranes
were hybridized for 24 hours at 428C using UltraHyb
(Ambion, Austin, TX) with approximately 13 106 cpm/mL
labeled antisense GHRH-R, Pit-1, and CREB probe, and 53
105 cpm/mL labeled antisense GH probe. Autoradiograms
and quantifications of intensity were done as described
above. Equal loading was confirmed, and data were
expressed as arbitrary units after correction for the 18S RNA.
Ribonuclease Protection Assay
Total RNA was hybridized overnight with approximately
600,000 cpm of labeled antisense rat IGF-I-R at 458C. The
hybridization solution contained 75% (vol/vol) formamide,
80 mM Tris-HCl (pH 7.6), 4 mM EDTA, 1.6 M NaCl, and
0.4% SDS. After hybridization, samples were digested using
RNase A (40 lg/mL) and RNase T1 (2 lg/mL) for 1 hour at
308C. Protected hybrids were isolated by ethanol pre-
cipitation after phenol–chloroform extraction and were
separated according to size on an 8% polyacrylamide/8 M
urea denaturing gel. Gels were exposed to x-ray film
(Kodak, Cambridge, U.K.) at 808C for 24–36 hours.
Quantification of the intensities of the autoradiogram bands
corresponding to protected hybrids was done by densito-
metric scanning as described above. All samples were
hybridized at the same time with 18S RNA to correct for the
differences in gel loading.
Semiquantitative Reverse Transcriptase–Polymerase
Chain Reaction
Total RNA isolated from pituitary extracts was used as
template for GHS-R, sstr2, sstr5, and GAPDH. Briefly, total
RNA (2 lg) was reverse transcribed using random primer
and Superscript II reverse transcriptase (RT; Invitrogen,
Carlsbad, CA). Sets of specific primers for rat GHS-R, sstr2,
sstr5, and GAPDH were designed using LightCycler Probe
Design Software 1.0 (Roche Diagnostics, Mannheim,
Germany) based on the sequence data of the gene available
in GeneBank (Table 1).
The sets of primers were used for LightCycler real time
polymerase chain reaction (PCR) using Sybr Green I (Roche
Applied Science, Indianapolis, IN). The reaction was
performed in a total volume of 20 lL in microcapillary tubes,
according to the manufacturer’s instructions. Each reaction
mixture contained 5 lL of cDNAs, 2 lL of FasterStart DNA
Master Sybr Green I mix, 2 lL of sense and antisense primers
each (0.5 lM), 2.4 lL of 25 mM MgCl2, and 6.6 lL of PCR-
grade H2O. The LightCycler programs for each gene were as
follows: denaturation (958C/10 minutes); PCR amplification
and quantification (958C/15 seconds, 58–608C/5 seconds,
728C/12 seconds) with single fluorescence measurement at the
Table 1. Primers Used in Polymerase Chain Reaction
Target Gene Gene Bank Accession Forward Primer (59 ! 39) Reverse Primer (59 ! 39) Length (bp)
GHS-Ra U94321 AGGCAACCTGCTCACTATGCTG GACAAGGATGACCAGCTTCAGC 292
sstr2 NM_019348 ATGTCTCTGCCGCTCTTG GCCAGGTTGACGATGTTG 217
sstr5 NM_012882 GCAGCCTTCATCACCTAC ACAAACACCAGCACCAC 317
GAPDH NM_017008 ACCCATCACCATCTTCC GGTTCACACCCATCACA 194
Note: GHS-Ra¼ GH secretagogue receptor alpha.
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end of the elongation step, repeated for 40 cycles. The
transition temperature at all steps was 208C/s. To verify that
only the specific product was amplified, a melting point
analysis was conducted after the final cycle. Specific
amplification was also confirmed by electrophoresis of PCR
products on 2% agarose gel.
Data acquisition and analysis were performed using
LightCycler software 3.5 (Roche). Threshold cycle (CT)
was determined by second derivative maximum analysis.
Specific standard curves for each gene were generated by
serial dilution (1 to 1/100) of total pituitary cDNAs to
determine the lineal amplification range and reaction
efficiency. All samples were tested in triplicate. Each run
included a nontemplate control to test for contamination of
assay reagents. For each sample the value of the housekeep-
ing gene GAPDH was analyzed as a standard for the quality
of the RNA samples investigated. No regulation of pituitary
GAPDH gene expression by age was confirmed by Northern
blot. Relative target mRNA expression from old to young
rats was calculated by using the 2CT method described
by Livak and Schmittgen (39).
Fixation, Staining, and Flow Cytometry of Cells
To assess the potential variation in the number of
somatotropes per pituitary with age, the percentage of GH-
positive cells was determined using immunofluorescence
flow cytometry. Pituitary cells were dispersed by the same
procedure used for primary culture, and immunostaining
performed using the reagent Fix&Perm Staining Cell
Permeabilization Kits (Caltag Laboratories, Burlingame,
CA), according to the protocol supplied by the manufacturer.
Cells were incubated with sheep antirat GH (1:1500;
NIDDKD). Then a second antibody conjugated to fluorescein
isothiocyanate (FITC; antisheep immunoglobulin G [IgG];
INC Biomedicals, Aurora, OH) and 7-amino-actinomycin D
(7-AAD; Via-Probe; BD PharMingen, Becton Dickinson Co.,
San Diego, CA) were added. The cells were then analyzed on
a FACScan Flow Cytometer (Becton-Dickinson, San Jose´,
CA). In parallel, one aliquot was treated with RNAse (Roche)
and propidium iodide as described (40) to assure that single
nuclear cells were analyzed. A gate was set in a 7-AAD
forward scatter (FSC) dot-plot so that only nucleated cells
were analyzed. The percentage of somatotropes was de-
termined in an FITC histogram.
Statistical Analysis
All data are expressed as the mean 6 standard error (SE).
Tests for significance between sample groups were
performed with a two-tailed t test. For multiple compar-
isons, analysis of variance (ANOVA) was used with
Fisher’s test for post hoc comparisons. Differences were
considered statistically significant if p , .05.
RESULTS
GH Gene Expression, IR-GH Reserve, and IR-GH
Secretion in Pituitary and Cell Extracts With Aging
To understand the mechanism of age-related decline in
GH secretion, GH mRNA levels and IR-GH content were
analyzed in pituitary extracts from rats of different ages. As
shown in Figure 1A, pituitary GH mRNA accumulation,
quantified by Northern blot, was markedly decreased in the
24-month rats (24m vs 3m 42.5 6 7.3%; p , .001).
Pituitary IR-GH content, which is equivalent to pituitary GH
reserve, showed a greater decrease in the 24-month group
(24m vs 3m 7.9 6 5.5%; p , .001) (Figure 1B). These
results indicate that the potential mechanism of this
alteration may be of transcriptional origin with the sub-
sequent effect on GH secretion.
To determine the behavior of the somatotropes from
young and old rats in our in vitro system, IR-GH release and
GH mRNA levels were analyzed in pituitary cells from old
and young rats from 4 to 72 hours. After the stabilizing
period, media were replaced and the cells were incubated for
another 72 hours. As shown in Figure 1C and D, GH mRNA
levels, quantified by Northern blot, were markedly decreased
in the 24-month rat cells after 4 and 72 hours in culture (24m
vs 3m 48.5 6 5.8% and 43.8 6 3.5, Figure 1C and D,
respectively; p , .001). A significantly reduced basal GH
secretion (Figure 1E) was observed in cells from 24-month
rats compared with cells from 3-month rats after 4 hours in
culture (p, .001); this reduced secretion was maintained for
the 72 hours of culture. These data indicate that, in our in
vitro system, somatotropes from both groups maintain the
characteristics observed in aged animals: a significant
decrease in GH secretion and GH mRNA levels, and a drastic
decreased IR-GH content (data not shown).
Pituitary Pit-1 Gene Expression in Aging Rats
The decline in GH gene expression with age is a con-
stitutive pituitary alteration that might result from a paral-
lel modification of some transcription factors specifically
involved in pituitary GH gene expression. As pituitary Pit-1
has been shown to bind to and activate the GH promoter, its
expression in the pituitary of old compared with young rats
was studied.
As depicted in Figure 2A, the presence of approximately
3.1 and 1.2 Kb Pit-1 mRNA transcripts was detected in the
anterior pituitaries of 3-month and 24-month rats. In
pituitaries from 24-month rats, the intensity of the 3.1 Kb
lane decreased when compared with that of the 3-month rats
(24m vs 3m 77 6 5.5%; p , .05), whereas the 1.2 Kb lane
did not change with age. The densitometric analysis of both
mRNA lanes together did not confirm a significant alteration
of Pit-1 expression with advancing age. Furthermore,
pituitary Pit-1 protein content quantified by Western blot
remained unchanged (Figure 2B). Therefore, no significant
differences in Pit-1 expression, measured either by mRNA
accumulation or protein content, were observed between
young and old rats.
Pituitary CREB Gene Expression With Aging
The GHRH transcriptional control of GH gene expression
seems to be mediated, at least in part, by the transcription
factor CREB. When 24-month and 3-month rats were
compared, no significant difference was observed in the
pituitary accumulation of CREB mRNA (Figure 3A); neither
was there any difference in CREB protein content or total and
phosphorylated forms (Figure 3B). These results indicate that
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in aging rats there is no alteration of the pituitary expression
of this transcription factor that could account for the GH gene
expression decay that occurs in aging.
Pituitary GHRH-R Gene Expression and Sensitivity of
Pituitary Cells to GHRH in Aging
The action of GHRH on GH gene expression and secretion
is mediated by the GHRH-R. Alterations of this receptor may
be relevant to understand the mechanism of the gradual
decay of GH in aging. Therefore, GHRH-R mRNA levels in
pituitary extracts from young and old rats were analyzed. As
shown in Figure 4A, the presence of 2.5 and 4 Kb GHRH-R
mRNA transcripts was detected in the anterior pituitaries of
3-month and 24-month rats. The relative abundance of the
two transcripts was significantly diminished in pituitaries
from 24-month rats compared with those of 3-month rats
(24m vs 3m: 23.6.76 6.7%, p, .001 and 42.16 3.8%, p,
.001 of 4 and 2.5 Kb transcripts, respectively). This
significant decrease of GHRH-R gene expression suggests
that this signaling pathway might have an important role in
driving the decline over age of GH secretion.
To determine the functional implication of the lower
GHRH-R mRNA content in pituitary cells from old rats,
we analyzed the capacity of GHRH to release GH from
cultured anterior pituitary cells from old and young rats,
and the ability of somatotropes to release GH upon
a receptor-independent stimulant of adenylyl cyclase such
as FK. Primary cultures of anterior pituitary cells from 3-
month and 24-month rats were treated with GHRH or FK
for 4 hours. As shown in Figure 4B, a reduced basal GH
secretion was maintained in cells from 24-month rats
compared with cells from 3-month rats (p , .01). The
exposure to GHRH or FK produced a significant increase
of GH secretion in the cells from the two groups. In the
cells from 24-month rats, the levels of IR-GH after
stimulation by both secretagogues were equal or even
greater than the basal values of cells from 3-month rats.
When the IR-GH secretory response was calculated after
correction for the basal absolute values and expressed as
fold increase over their corresponding basal secretion,
there was not any significant difference in the response
between the two groups (GHRH: 3m, 2.68 6 0.19; 24m,
2.61 6 0.09 and FK: 3m, 2.87 6 0.24; 24m, 3.01 6 0.18)
(Figure 4C). These results suggest that the pituitary cells
from old rats maintain the same capacity as the cells from
young rats to respond to exogenous GHRH, and that the
lower absolute response of the old rats is brought about by
their lower GH content reserve.
Figure 1. Pituitary growth hormone (GH) messenger RNA (mRNA) levels, immunoreactive rat (IR)-GH content and secretion, and GH mRNA levels in
somatotropes from young (3-month [3m]) and old (24m) rats in culture. A, Pituitary GH mRNA levels were measured by Northern blot. Upper panel: representative
Northern blot. Lower panel: quantification of GH mRNA bands by scanning densitometry. Two micrograms of total pituitary RNA was subjected to Northern blot
using GH probe. After correction for 18s levels, optical density units were adjusted so that the ratio obtained from pituitaries of 3m rats equaled 100. B, IR-GH content
was measured by radioimmunoassay (RIA). Values were adjusted so that the values obtained from pituitaries of 3m rats equaled 100. C and D, GH mRNA levels were
measured by Northern blot. Pituitary cells from the two groups were cultured for 4 (C) or 72 hours (D). Upper panel: representative Northern blot. Lower panel:
quantification of GH mRNA bands by scanning densitometry. Northern blot and data evaluation were performed as in A. E, Somatotrope IR-GH secretion. Pituitary
cells from young and old rats were cultured for 72 hours. Aliquots of medium were obtained at 4, 8, 24, 48, and 72 hours to measure IR-GH secretion by RIA. Values
represent mean 6 standard error (n ¼ 12). ***p , .001 vs 3m group. a.d.u., arbitrary densitometric units.
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Pituitary GHS-R Gene Expression and Sensitivity of
Pituitary Cells to Ghrelin With Increasing Age
Given that ghrelin plays an important role in the phys-
iological regulation of GH by acting also at the pituitary level,
GHS-R mRNA levels were quantified by real time RT-PCR in
pituitary extracts from rats of different ages. A significant
decrease in the levels of GHS-R mRNA was observed in 24-
month rats (24m vs 3m 36.8 6 7.4%; p , .01) (Figure 5A).
These data indicate an alteration of pituitary GHS-R gene
expression that might contribute to a decrease in pituitary
ghrelin efficacy and/or intensity of signalling with age.
To assess this possibility, cultured anterior pituitary cells
from young and old rats were treated with ghrelin for 4
hours. As described previously, a reduced basal GH
secretion was observed in cells from 24-month rats,
compared with cells from 3-month rats (p , .001) (Figure
5B). The exposure to ghrelin produced a significant increase
of GH secretion in the cells from the two groups. When the
IR-GH secretory response was calculated after correction for
the basal absolute values and expressed as fold increase over
their corresponding basal secretion, there was no significant
difference in the response (3m: 1.54 6 0.03; 24m: 1.48 6
0.05) (Figure 5C). These data indicate that pituitary cells
from old rats maintain the same capacity to respond to
exogenous ghrelin as the cells from young rats.
Pituitary sstr2 and sstr5 Gene Expression
and Sensitivity of Pituitary Cells to
SS With Increasing Age
SS is the major inhibitory signal of GH secretion;
therefore, mRNA levels of sstr2 and sstr5 subtypes, the
most highly expressed in the pituitary and functionally
Figure 3. Pituitary cAMP-response element-binding protein (CREB) mes-
senger RNA (mRNA) levels and CREB protein in young (3 month [3m]) and old
(24m) rats. A, CREB mRNA levels were measured by Northern blot. Upper
panel: representative Northern blot. Lower panel: quantification of CREB
mRNA bands by scanning densitometry. Fifteen micrograms of total pituitary
RNA was subjected to Northern blot using CREB probe. After correction for 18s
levels, optical density units were adjusted so that the ratio obtained from
pituitaries of 3m rats equaled 100. B, CREB and phospho-CREB (P-CREB)
proteins were measured by Western immunoblot. Upper panel: representative
Western blot of total CREB. Middle panel: representative Western immunoblot
of P-CREB. Lower panel: quantification of total CREB and P-CREB by
scanning densitometry. Ten micrograms of protein from pituitary extracts were
subjected to Western immunoblot. Optical density units were adjusted so that
the values obtained from pituitaries of 3m rats equaled 100. Values represent
mean 6 standard error (n ¼ 12). a.d.u., arbitrary densitometric units.
Figure 2. Pituitary Pit-1 messenger RNA (mRNA) levels and Pit-1 protein in
young (3 month [3m]) and old (24m) rats. A, Pit-1 mRNA levels were measured
by Northern blot. Upper panel: representative Northern blot. Middle and lower
panels: quantification of 3.1- and 1.2 Kb Pit-1 transcript bands by scanning
densitometry. Fifteen micrograms of total pituitary RNA was subjected to
Northern blot using Pit-1 probe. After correction for 18s levels, optical density
units were adjusted so that the ratio obtained from pituitaries of 3m rats equaled
100. B, Pit-1 protein was measured by Western immunoblot. Upper panel:
representative Western blot. Lower panel: quantification of Pit-1 by scanning
densitometry. Ten micrograms of protein from pituitary extracts were subjected
to Western immunoblot. Optical density units were adjusted so that the values
obtained from pituitaries of 3m rats equaled 100. Values represent mean 6
standard error (n ¼ 12). *p , .05. n.s., not significant vs 3m group; a.d.u.,
arbitrary densitometric units.
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active of SS receptors, were analyzed by real time RT-PCR
in pituitary extracts from rats of different ages. As shown in
Figure 6A and B, a significant decrease in the levels of sstr2
and sstr5 was observed in 24-month rats compared with
3-month rats (24m vs 3m: 61.58 6 5.7% Figure 6A and
58.67 6 4.3% Figure 6B, respectively; p , .01).
It has been postulated that a higher pituitary sensitivity to
the SS signal may be the mechanism involved in the
decrease of GH secretion in aging. Because we found
a lower expression of SS receptor in pituitary of old rats, we
studied the pituitary sensitivity to SS in relation to age. To
this end, cultured anterior pituitary cells from 3-month and
24-month rats were treated with SS for 4 hours. The
exposure to SS produced a significant decrease of GH
secretion in the cells from the two groups (Figure 6C).
When the SS effect on IR-GH secretion was calculated after
correction for the basal absolute values and expressed as
a percentage of their corresponding basal secretion, there
was no significant difference between the 3-month and
24-month rats (3m: 45.5 6 3.8%; 24m: 59.7 6 8% vs their
own controls) (Figure 6D).
To test for the inhibitory effect of SS on GHRH- and
ghrelin-induced GH secretion, cultured anterior pituitary
cells from 3-month and 24-month rats were treated with
GHRH or ghrelin alone or plus SS for 4 hours. As described
above, the exposure of pituitary cells to GHRH and ghrelin
significantly increased GH secretion in the cells of both
groups (Figure 6E and F). The addition of SS partially
inhibited GHRH-induced GH secretion in both groups
(3m: 50%; 24m: 41% vs each corresponding GHRH-treated
group) and reduced the ghrelin-induced GH secretion below
the basal GH values in both groups (3m: 47%; 24m 41% vs
each corresponding ghrelin-treated group). A tendency to
lower sensitivity to SS, both on basal IR-GH secretion and
on GHRH- and ghrelin-induced IR-GH secretion was
observed in the cells from old rats. These results suggest
that an increased sensitivity to SS does not appear to be
responsible for the gradual decline of GH secretion with
advancing age.
Pituitary IGF-I-R Gene Expression and Sensitivity of
Pituitary Cells to IGF-I in Aging
To study the potential implication of IGF-I in the decline
of GH with aging, pituitary IGF-I-R and protein content
were analyzed by RNAse protection assay and Western blot,
Figure 4. Pituitary growth hormone releasing hormone receptor (GHRH-R)
messenger RNA (mRNA) levels and sensitivity of pituitary cells to GHRH in
relation with age. A, Pituitary GHRH-R mRNA levels were measured by
Northern blot. Upper panel: representative Northern blot. Lower panel:
quantification of GHRH-R mRNA bands by scanning densitometry. Fifteen
micrograms of total pituitary RNA from young (3 month [3m]) and old (24m)
rats were subjected to Northern blot using GHRH-R probe. After correction for
18s levels, optical density units were adjusted so that the ratio obtained from
pituitaries of 3m rats equaled 100. Values represent mean 6 standard error (SE)
(n ¼ 12). ***p , .001 vs 3m group. a.d.u., arbitrary densitometric units. B,
Response of pituitary cells to GHRH. Pituitary cells of young and old rats were
incubated in the absence or presence of GHRH (108 M) or forskolin (FK; 1 lM)
for 4 hours. Figure represents immunoreactive rat (IR)-GH in culture medium.
Data were adjusted so that values obtained in untreated pituitary cells from 3m
rats equaled 100. C, Results are expressed as fold increase of the IR-GH
response to GHRH or FK after correction for the basal absolute values. Values
represent mean 6 SE of four experiments (n ¼ 16). ***p , .001 vs their
respective age control group.
Figure 5. Pituitary growth hormone secretagogue receptor (GHS-R) messen-
ger RNA (mRNA) levels and sensitivity of pituitary cells to ghrelin in relation
with age. A, GHS-R mRNA levels were measured by real time polymerase chain
reaction (PCR). Two micrograms of total pituitary RNA from young (3 month
[3m]) and old (24m) rats was reverse transcribed, amplified, and quantified by
real time PCR as described in Methods. After correction for GAPDH levels, the
data were adjusted so that the values obtained from pituitaries of 3m rats equaled
100. Values represent mean 6 SE (n ¼ 12). **p , .01 vs 3m group. a.u.,
arbitrary units. B, Response of pituitary cells to ghrelin. Pituitary cells of young
and old rats were incubated in the absence or presence of ghrelin (106 M) for
4 hours. Figure represents immunoreactive rat (IR)-GH in culture medium. Data
were adjusted so that the values obtained in untreated pituitary cells from 3m rats
equaled 100. C, Results are expressed as fold increase of the IR-GH response to
ghrelin after correction for the basal absolute values. Values represent mean 6
SE of four experiments (n ¼ 16). ***p , .001 vs their respective age control
group.
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respectively. As shown in Figure 7A and B, both IGF-I-R
mRNA and protein levels were similar in young and
old rats.
It has been postulated that a higher pituitary sensitivity to
IGF-I may account for the decrease of GH secretion in
aging. To clarify this point, we studied the pituitary
sensitivity to IGF-I in relation to age. To this end, cultured
anterior pituitary cells from 3-month and 24-month rats
were treated with IGF-I for 72 hours. The exposure to IGF-I
produced a significant decrease of GH mRNA levels and IR-
GH secretion in the cells from the two groups (Figure 7C
and E). When this effect was expressed as a percentage of
their corresponding basal values, there was no significant
difference in the inhibitory effect of IGF-I on GH mRNA
and IR-GH secretion between the 3-month and 24-month
rats (GH mRNA levels: 3m, 41 6 8.9%; 24m, 52 6 18%
and IR-GH: 3m, 44 6 17%; 24m, 61 6 10.2% vs their own
controls) (Figure 7D and F). There was a trend for reduced
sensitivity to IGF-I in the cells from old rats. These data
indicate that an increased sensitivity to IGF-I is not involved
in the mechanism of the GH gene expression and GH
secretion decline with advancing age.
Somatotrope Population in Aging Pituitaries
To answer the traditional question of a potential age-
related alteration in the relative proportion of differentiated
pituitary cells, cytometric studies were done.
The dissociation procedure yielded about 2.83 106 cells
per anterior pituitary gland in 3-month rats and 5.7 3 106
cells per anterior pituitary gland in 24-month rats (24m vs
3m, 203 6 12.3%; p , .001). Cell viability, as measured
by 7-AAD exclusion test, was .90% in both 3-month and
24-month cells, with no significant difference. There was no
change in the percentage of pituitary cells immunoreactive
to GH with aging, quantified by flow cytometry (Figure 8C).
These data together suggest an increase in the total number
of cells together with a relative increase of GH secretory
cells in the pituitaries from old rats.
DISCUSSION
Reduction of the GH/IGF-I axis activity is a hallmark of
the hormonal changes with aging. The GH/IGF-I decrease in
senescence has important clinical implications, particularly
as GH deficiency might contribute to the gradual decline in
tissue functions associated with normal aging (1). The main
goals of the present studies were to elucidate whether the
decrease in GH secretion during aging is a pituitary-
constitutive alteration and to determine the potential re-
versibility of the GH secretion decay by analyzing the
pituitary capacity to respond to different stimuli. The key
findings of the present study include the demonstration that
aging does not modify Pit-1 and CREB expression and does
not cause a decrease in the somatotrope population. More-
over, the adenylyl cyclase–cAMP pathway remains un-
altered in the old somatotropes. Additionally, we show that
the sensitivity of somatotropes to ghrelin, to the inhibition
by SS of GHRH- and ghrelin-induced GH and to IGF-I is
not modified by aging.
In this study, we confirm our previous findings (8,9,41),
which showed that GH gene expression, pituitary IR-GH
content, and GH secretion diminish with age. The decrease
in GH secretion rate, demonstrated by the decrease in GH
amplitude or frequency of pulses (7), appears to be
dependent on the lower pituitary reserve due to a decrease
in GH gene expression, indicating that a transcriptional
mechanism might account for the decline in GH secretion
that occurs with aging. The concept that GH is regulated by
different developmental stages (such as puberty and aging)
Figure 6. Pituitary somatostatin (SS) receptor subtypes messenger RNA
(mRNA) levels and sensitivity of pituitary cells to SS in young (3 month [3m])
and old (24m) rats. Pituitary sstr2 (A) and sstr5 (B) mRNA levels were measured
by real time polymerase chain reaction (PCR). Two micrograms of total pituitary
RNA was reverse transcribed, amplified, and quantified by real time PCR as
described in Methods. After correction for GAPDH levels, the data were
adjusted so that the values obtained from pituitaries of 3m rats equaled 100.
Values represent mean 6 standard error (SE) (n¼ 12). **p , .01 vs 3m group.
a.u., arbitrary units. C, Response of pituitary cells to SS. Pituitary cells of young
and old rats were incubated in the absence or presence of SS (109 M) for 4
hours. Figure represents immunoreactive rat (IR)-GH in culture medium. Data
were adjusted so that values obtained in untreated pituitary cells from 3m rats
equaled 100. D, Results are expressed as percentage of their respective age
control group. E, Effect of SS on growth hormone releasing hormone (GHRH)-
induced GH secretion. Pituitary cells of young and old rats were incubated in
the absence or presence of GHRH (108 M) or GHRHþSS (109 M). Figure
represents IR-GH in culture medium. Results are expressed as percentage of
their respective age control group after correction for the basal absolute values.
F, Effect of SS on ghrelin-induced GH secretion. Pituitary cells of young and old
rats were incubated in the absence or presence of ghrelin (106 M) or ghrelinþSS
(109 M). Figure represents IR-GH in culture medium. Results are expressed as
percentage of their respective age control group after correction for the basal
absolute values. Values represent mean 6 SE of four experiments (n ¼ 16).
*p , .05, **p , .01, ***p , .001 vs their respective age control group.
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in animals and humans is strongly supported by our results.
Thus, puberty could be a model of GH gene overexpression
and secretion, and aging a profile of relative or partial GH
deficiency.
We also found that after 6 days in vitro the cumulative
GH secretion and GH mRNA levels are lower in pituitary
cells from old rats, which indicates that in our in vitro
system the cultured somatotropes retain the characteristics
observed in vivo.
Pituitary-specific expression of the GH gene is Pit-1
dependent (23). Given that Pit-1 and GH promoters are
stimulated by cAMP, we studied the potential alteration
with age of the pituitary transcription factors Pit-1 and
CREB, both of which are involved in GH gene expression.
Our results indicate that the pituitary expression of the
transcription factors Pit-1 and CREB in old rats is not
significantly different from that in young rats. Similar Pit-1
results were obtained in Sprague-Dawley rats by Korytko
Figure 7. Pituitary insulin-like growth factor I (IGF-I) receptor messenger RNA (mRNA) levels and IFG-I receptor (IGF-I-R)b protein and sensitivity of pituitary
cells to IGF-I in young (3 month [3m]) and old (24m) rats. A, IGF-I-R mRNA levels were measured by RNase protection assay. Upper panel: representative gel. Lower
panel: quantification of IGF-I-R mRNA protected fragment by scanning densitometry. Ten micrograms of total pituitary RNA was subjected to solution hybridization/
RNase protection assay using the antisense IGF-I-R and 18S probes. The positions of each protected fragment are indicated on the right. Lane 1: molecular-weight
marker. Lane 2: transfer ribonucleic acid (tRNA) control. Lane 3: undigested IGF-I-R probe. Lane 4: undigested 18S probe. Lane 5: IGF-I-R and 18S probes after
RNase A and T1 digestion. B, IGF-I-Rb protein was measured by Western immunoblot. Upper panel: representative Western blot. Lower panel: quantification of IGF-
I-Rb by scanning densitometry. Ten micrograms of protein from pituitary extracts was subjected to Western blot. Optical density units were adjusted so that the values
obtained from pituitaries of 3m rats equaled 100. Values represent mean 6 standard error (SE) (n¼12). n.s., not significant vs 3m group; a.d.u., arbitrary densitometric
units. C, Effect of IGF-I on growth hormone (GH) mRNA levels in pituitary cells measured by Northern blot. Pituitary cells of young and old rats were incubated in the
absence or presence of IGF-I (6 nM) for 72 hours. Upper panel: representative Northern blot. Lower panel: quantification of GH mRNA bands by scanning
densitometry. Two micrograms of total cellular RNA was subjected to Northern blot using GH probe. After correction for 18s levels, optical density units were adjusted
so that the ratio obtained from 3m rats equaled 100. D, Results are expressed as percentage of their respective age control group after correction for the basal absolute
values. E, Effect of IGF-I on immunoreactive rat (IR)-GH secretion. Pituitary cells of young and old rats were incubated in the absence or presence of IGF-I (6 nM) for
72 hours. Figure represents IR-GH in culture medium. Data were adjusted so that values obtained in untreated pituitary cells from 3m rats equaled 100. F, Results are
expressed as percentage of their respective age control group after correction for the basal absolute values. Values represent mean 6 SE (n¼ 16). *p , .05, **p , .01,
***p , .001 vs their respective age control group. a.d.u., arbitrary densitometric units.
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and colleagues (42), who found no difference in Pit-1
mRNA levels when analyzing pituitaries from 70-day and
12-month rats. In 18-month rats of the same strain,
Gaudreau (43) observed no change in Pit-1 mRNA or
protein compared with younger rats. Similar findings have
been shown in rats with streptozotocin-induced diabetes,
where the decrease in GH gene expression is not related to
changes of Pit-1 expression (44). However a decrease of
Pit-1 gene expression in old female mice has been described
in a recent study (45). There are not positive data showing
that CREB might be involved in this mechanism which is in
agreement with the results found in this study. These data
strongly suggest that changes in the expression of these
transcription factors are unlikely to contribute to the gradual
downfall of GH secretion with advancing age.
We next studied whether the specific receptors of the
three major regulatory signals of GH secretion—growth
hormone-releasing hormone (GHRH), ghrelin, and somato-
statin (SS)—might be involved in the decline of GH in
aging. We found that a significant decrease in the pituitary
levels of GHRH-R, GHS-R, sstr2, and sstr5 mRNAs occurs
in aging. Our results confirm previous studies with respect
to GHRH-R. In fact, a progressive decrease of GHRH-R
levels in rats of 6 and 24 months of age has been described
(46). In another study of 18-month rats, a decrease of the
GHRH-R 2.5 Kb transcript that exhibits high-affinity
binding and functionality (47), and an increase of the 4
Kb transcript but with a decrease in the total GHRH-R
mRNA was found in the old rats compared with young
rats (48). As to pituitary age-related GHS-R gene expres-
sion, there is only one study in old female mice that
confirms our finding of lower GHS-R mRNA in older rats.
In the same study, a diminution of the sstr2 and sstr5 mRNA
levels in the pituitary of older mice is in agreement with our
results in the rat (45). A more recent study, in rats of 16-
months, confirmed a decrease of sstr2 and sstr5 mRNA
levels compared with younger rats (46).
Therefore, an age-related decline in the pituitary gene
expression of the receptors involved in the regulation of GH
gene expression and secretion, including those related with
stimulatory effects (such as GHRH and ghrelin) and with
inhibitory action (such as SS), is clearly established. This
age-related perturbation could be a primary event but most
probably is caused by a drop of hypothalamic GHRH (49),
as the expression of GHRH-R, GHS-R, and sstr2 is
stimulated by this signal. In an in vitro study in adult male
rats, a critical effect of GHRH on GHRH-R mRNA
accumulation was found to be related to the duration of
GHRH exposure; thus, 72-hour exposure stimulated
GHRH-R mRNA over the control values (50). Another
recent study in ovine somatotropes has shown that GHRH
treatment in vitro increased the levels of GHRH-R and
GHS-R mRNA (51). This hypothesis is also supported by
other studies which showed that in spontaneous dwarf rats
(SDR), in which a mutation of the GH gene results in total
absence of the hormone, treatment with GHRH stimulated
GHRH-R, GHS-R, and sstr2 gene expression (52) but
inhibited sstr5. However, in normal pituitary cells, when
exposed for 4 hours to GHRH, GHRH-R and sstr5 mRNA
levels decreased, whereas those of GHS-R and sstr2
increased. This opposite effect of GHRH on the regulation
of SS receptor has been confirmed in another study that
showed that GHRH administration increased sstr2 mRNA
and decreased sstr5 mRNA levels in rat pituitaries (53). As
the decrease of GHRH would not seem to explain the
diminished sstr5 expression, other still unknown mecha-
nisms might be implicated. Some authors support the
hypothesis that hypothalamic SS upregulates pituitary
SS-receptor subtype levels (54,55). These early reports,
carried out in pituitary cell lines, showed that after 24 and 48
hours SS can increase sstr levels, but the response of sstr2 to
SS is mainly biphasic and relative to the time of exposure to
the peptide. A more recent report on cultured rat pituitary
cells demonstrated that SS increases sstr5 and has no effect
on sstr2 (56). In vivo studies have shown that the
immunoneutralization of endogenous SS does not alter
basal or GHRH-mediated SS-receptor subtype expression
(53,57). The discrepancy between these data may be due to
the fact that the in vitro studies examined the effect of
exogenous SS stimulation, whereas the in vivo studies
examined the effect of the suppression of endogenous SS;
there could have been compensatory mechanisms in these in
vivo studies. Therefore, if SS really upregulated sstr5, the
drop in pituitary sstr5 with advancing age may reflect the
decrease of hypothalamic SS. These findings suggest that
the decline of the GH/IGF-I system with age is not
a constitutive primary pituitary alteration and open up the
possibility that the GH pituitary alterations of aging might
be reversible. Our data and those from other authors have
Figure 8. Growth hormone-labeled cells in the pituitaries from young (3
month [3m]) and old (24m) rats. A, Distribution of pituitary cells on 7-amino
actinomycin/forward scatter (7-AAD/FSC) diagram used to select nucleated
cells. B, Representative fluorescein isothiocyanate (FITC) fluorescence histo-
gram of pituitary cells from 3m and 24m rats. Dashed line: control; black line:
GH-expressing cells. C, Percentage of immunoreactive GH-positive cells
relative to the total number of cells. Values represent mean 6 standard error
(n ¼ 8).
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shown that somatotropes comprise approximately half of
young and old pituitary cells in humans and rats (58,59).
Within the pituitary, GHS-R, sstr2, and sstr5 are expressed
in somatotropes together with other pituitary cells (60,61).
The age-related changes in pituitary GHS-R, sstr2 and sstr5
most likely reflect changes that occur in the somatotropes,
although other pituitary cells may also play a role.
At present, the in vivo and in vitro sensitivity of old
pituitary cells to GHRH is a matter of controversy, and there
are not well-established data in either aging humans or
aging rats. The in vivo response to GHRH has been
described either as a diminution with age both in humans
(62) and in rats (30) or as a response of the same magnitude
in aging men (31,63) and rats (64). In in vitro studies,
a diminution (65) or no change (30,33) in the somatotrope
responsiveness to GHRH with age has been found. The in
vivo studies of sensitivity to GHS with age showed a lower
GH response to GHS with age (32). It is difficult to assess
a direct pituitary action of GHS on GH release in in vivo
studies because of the releasing activity of GHS on
hypothalamic GHRH. There are no reliable in vitro studies
concerning this issue. Our data indicate that the relative
response of IR-GH to GHRH, FK, and ghrelin was not
significantly different between young and old pituitary cells
when compared with their own basal secretion and
expressed as fold increase. Furthermore, in cells from old
rats, the levels of IR-GH secreted after a pharmacological
stimulus with high doses of GHRH and FK were similar to
those found in the unstimulated cells from young rats.
Therefore, old somatotropes maintain the normal physio-
logical capacity to respond to secretagogues, although the
higher GH reserve of young cells determines a greater
absolute IR-GH response. These data indicate that the lower
GH secretion that occurs with aging could be reversed by
GHRH, as has been reported, and support that secreta-
gogues are an alternative treatment for GH deficiency in
elderly people.
Earlier studies, carried out in vivo or in superfused
pituitary slices, indicated that the sensitivity of old
somatotropes to SS was increased (33,66). Our results,
obtained in different experimental conditions, indicate that
SS inhibits basal and GHRH- and GHS-induced GH release
with similar intensity in young and adult pituitary cells.
Thus, our results suggest that the sensitivity of pituitary cells
to SS does not increase with age, which is in agreement with
other authors who observed that SS equally inhibits the GH
release in pituitary cells or fragments of old and young rats
(67,68). These results, together with the decrease of sstr2
and sstr5 expression (the two SS receptor types most
functional in the pituitary) and the decrease of SS in the
median eminence (29) and in hypothalamic extracts (7,69),
question the hypothesis of an increased somatostatinergic
tone as the mechanism of the GH expression and secretion
waning that occurs in aging. There are also reports showing
increased SS levels in the hypothalamus of aged rats (70) or
supporting an age-related increase in the efficiency of
translation of SS mRNA (71).
Our study on IGF-I, another inhibitory factor of GH
secretion, does not support that IGF-I plays a role in the
mechanism of GH decline in old rats. We observed no
alteration of IGF-I-R mRNA levels and IGF-I-R protein
content in the pituitaries of aging rats. Our findings agree
with data from food-deprived rats, in which the decrease in
GH and IGF-I serum levels is not accompanied with parallel
pituitary changes in IGF-I-R mRNA (72). In addition, our
results indicate that the sensitivity of pituitary cells to IGF-I
does not increase with age. Chapman and colleagues (37)
obtained similar results in a study of elderly persons in
whom they blocked the fasting-induced GH with exogenous
IGF-I, and observed that the IGF-I treatment decreased GH
serum levels to a lesser extent in aged men than in young
men, despite the fact that IGF-I serum levels were greater in
the older than the younger men. This in vivo study was
unable to establish whether the IGF-I feedback occurs at the
pituitary or hypothalamic level. Our study, which analyzes
the direct effect of IGF-I on somatotropes in aging, together
with the well-known decline of circulating IGF-I, clearly
rules out that changes in IGF-I action at the pituitary level
may account for the decline of GH in aging.
Although it has been demonstrated that the pituitary of
old rats is heavier than that of young rats, a reduction in the
population of pituitary somatotropes has been postulated as
a mechanism involved in the diminution of GH secretion of
aging. Our results confirm an increase in the total cell
number per pituitary in aging rats as shown in previous
studies in pituitaries dissociated from 26-month rats (73)
and 20-month rats (67). We have also observed that the
percentage of GH immunoreactive cells was similar in
the pituitaries from young and old rats. Other studies in old
pituitaries have described a decrease in the somatotrope
population by immunohistochemical quantification of pitui-
tary sections (74,75). The differences in species, rat strains,
and methodologies used probably account for the variance
in results among the studies. Our results strongly suggest
that a diminution in the number of somatotropes is not the
mechanism of the GH secretion decline of senescence and
indicate that, at least in the rat, there is an increase in the
total number of GH cells per pituitary with aging. This
statement is also supported by the earlier results of Rossi
and colleagues (76) who observed that somatotrope number
increased in pituitaries of male rats of advanced age. Given
that hypothalamic GHRH, which stimulates somatotrope
proliferation (77), is decreased in old male rats (49), it is not
clear what causes the increase in the number of somato-
tropes in the aging male rats.
Summary
This study demonstrates some age-related pituitary
perturbations such as the decrement of pituitary IR-GH
content and mRNA levels, and a lower expression of
pituitary receptors: GHRH-R, GHS-R, sstr2, sstr5, and IGF-
I-R. Moreover, we have found that aging does not modify
Pit-1 and CREB expression in the pituitary and does not
cause a decrease of somatotrope population. Additionally,
we demonstrate that the capacity of GH response to
pharmacological doses of secretagogues is not altered in
cells from aging rats, and that the pituitary cells from old
rats do not show a greater sensitivity to SS or IGF-I. Our
results give experimental support to the concept of
reversibility of the pituitary alteration of the GH/IGF-I
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system that occurs with aging, at least with direct pituitary
stimulation of endogenous GH secretion with GHRH and
other secretagogues.
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